Trial Profile
Open-label Phentermine/Topiramate Extended Release (PHEN/TPM ER; Qsymia) in Ten Subjects With Overweight or Obesity and DSM-V Binge Eating Disorder (BED)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2016
Price :
$35
*
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Binge-eating disorder
- Focus Therapeutic Use
- 19 Sep 2016 Status changed from recruiting to completed.
- 04 Feb 2016 New trial record